文献速递心境障碍

难治性抑郁症的药物治疗:抗精神病药在快速演变格局中的定位

Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
PubMed 文献 · Am J Psychiatry · 2023-01-01

约三分之一重性抑郁障碍(MDD)成人对抗抑郁药序贯治疗反应不足,构成难治性抑郁症(TRD)。本文综述FDA批准用于抑郁症的非典型抗精神病药(阿立哌唑、依匹哌唑、卡利拉嗪、喹硫平缓释片、奥氮平-氟西汀复方)的急性期疗效与副作用负担,并讨论快速起效抗抑郁药和管线药物对TRD治疗格局的影响,呼吁开展实效性试验比较不同策略及最佳序贯顺序。

要点

  • TRD指对一种或多种抗抑郁药足量足疗程反应不足,约三分之一MDD成人符合此情况。
  • FDA批准用于抑郁症的非典型抗精神病药包括阿立哌唑、依匹哌唑、卡利拉嗪、喹硫平缓释片和奥氮平-氟西汀复方。
  • 非典型抗精神病药急性期可改善抑郁症状,但临床治愈有限,长期使用需关注体重增加、代谢紊乱、EPS和迟发性运动障碍。

核心结论

  • 非典型抗精神病药是TRD的有效辅助治疗选择,但临床治愈率有限且长期副作用显著,需在快速演变的治疗格局中重新定位。
  • 需要实效性试验比较非典型抗精神病药与TRD专用药物及神经调控治疗的效果,并确定最佳序贯顺序。

研究设计与样本

  • 本文为叙述性综述,未报告系统检索策略、纳入研究数量或样本量。
  • TRD定义采用宽泛标准:对一种或多种抗抑郁药治疗反应不足。

主要发现

  • 约三分之一MDD成人对多种序贯抗抑郁药无临床显著改善,构成TRD。
  • 多种急性期研究显示非典型抗精神病药可改善抑郁症状,但临床治愈(缓解)仍然有限。
  • 非典型抗精神病药长期使用与体重增加、代谢功能障碍、锥体外系症状和迟发性运动障碍相关。
  • 近年来FDA批准了艾司氯胺酮鼻喷雾剂和右美沙芬-安非他酮复方等快速起效抗抑郁药,zuranolone和psilocybin等处于后期研发管线。

关键数值与推荐

  • FDA批准用于抑郁症的非典型抗精神病药包括阿立哌唑、依匹哌唑、卡利拉嗪、喹硫平缓释片和奥氮平-氟西汀复方。

临床怎么用

  • 使用非典型抗精神病药治疗TRD时,应基于预期副作用、耐受性、成本和可行性个体化选择,并采用共享决策。
  • 需关注长期使用非典型抗精神病药相关的体重增加、代谢紊乱、EPS和迟发性运动障碍。
  • 在快速起效抗抑郁药和管线药物不断涌现的背景下,需重新评估非典型抗精神病药在TRD治疗序贯中的位置。

局限性

  • TRD缺乏共识定义,本文采用宽泛定义可能影响结论的普适性。
  • 缺乏非典型抗精神病药与TRD专用药物及神经调控治疗的头对头实效性比较证据。
  • 未报告系统检索策略、纳入研究数量或偏倚评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD). The presence of TRD contributes to the morbidity and excess mortality associated with MDD and has been linked to significantly increased health care expenses. In the absence of a consensus definition of TRD, this report takes a broad approach by considering inadequate response to one or more courses of antidepressants and focuses on atypical antipsychotics that are approved by the U.S. Food and Drug Administration for treatment of depression (aripiprazole, brexpiprazole, cariprazine, extended-release quetiapine, and olanzapine-fluoxetine combination). While multiple acute-phase studies have demonstrated the efficacy of these medications in improving depressive symptoms, clinically meaningful improvement (i.e., remission) remains limited, with significant concerns about side effects (including weight gain, metabolic dysfunction, extrapyramidal symptoms, and tardive dyskinesia), especially with long-term use. With the rapidly evolving landscape of antidepressant treatments over the past few years, which has witnessed approval of rapid-acting antidepressants (e.g., esketamine nasal spray and dextromethorphan-bupropion combination) and several more in the late-stage pipeline (e.g., zuranolone and psilocybin), it remains to be seen whether the use of atypical antipsychotics will go the way of the older and rarely prescribed antidepressants (such as tricyclics and monoamine oxidase inhibitors). Pragmatic clinical trials are needed to compare the effectiveness of atypical antipsychotics with TRD-specific pharmacotherapies and neuromodulation treatments and to identify the optimal sequencing of these varied approaches for patients with MDD. When using atypical antipsychotics, clinicians and patients are encouraged to use a shared decision-making approach by personalizing treatment selection based on anticipated side effects, tolerability, cost, and feasibility.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Jha MK, Mathew SJ. Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. Am J Psychiatry. 2023. PMID: 36855876. doi:10.1176/appi.ajp.20230025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。